Canaccord analyst William Plovanic lowered the firm’s price target on AtriCure (ATRC) to $51 from $52 and keeps a Buy rating on the shares. The firm said posted a solid Q1, with revenue relatively in line with estimates and the company continuing to show better than expected adjusted EBITDA. and they continue to believe that AtriCure is a compelling name, especially given the muted tariff exposure and impacts.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- Atricure’s Strong Q1 2025 Performance and Conservative Guidance Justifies Buy Rating Despite Price Target Adjustment
- AtriCure, Inc. Reports Strong Q1 2025 Growth
- AtriCure sees FY25 revenue $517M-$527M, consensus $522.85M
- AtriCure reports Q1 adjusted EPS (14c), consensus (22c)
- ATRC Upcoming Earnings Report: What to Expect?